Vergleich

Dexamethasone

ArtNr CS-1505-500mg
Hersteller ChemScene
CAS-Nr. 50-02-2
Menge 500mg
Kategorie
Typ Molecules
Specific against other
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Alias 50-02-2
Similar products 50-02-2
Lieferbar
Alternative Names
Hexadecadrol; Prednisolone F
CAS
50-02-2
Purity
>98%
MWt
392.46
Formula
C22H29FO5
Solubility
Ethanol : 8.33 mg/mL (21.23 mM; Need ultrasonic); DMSO : >= 56 mg/mL (142.69 mM); H2O : >= 1 mg/mL (2.55 mM)
Clinical Information
Launched
Pathway
GPCR/G Protein; Anti-infection; Autophagy; Anti-infection; Immunology/Inflammation; Autophagy; Anti-infection
Target
Glucocorticoid Receptor; Bacterial; Autophagy; SARS-CoV; Complement System; Mitophagy; Antibiotic
Biological Activity
Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses. IC50 & Target: Glucocorticoid receptor[1] In Vitro: Dexamethasone (Hexadecadrol) regulates several transcription factors, including activator protein-1, nuclear factor-AT, and nuclear factor-kB, leading to the activation and repression of key genes involved in the inflammatory response[1].
Dexamethasone potently inhibits granulocyte-macrophage colony stimulating factor (GM-CSF) release from A549 cells with EC50 of 2.2 nM. Dexamethasone (EC50=36 nM) induces transcription of the beta2-receptor is found to correlate with glucocorticoid receptor (GR) DNA binding and occurred at 10-100 fold higher concentrations than the inhibition of GM-CSF release. Dexamethasone (IC50=0.5 nM) inhibits a 3xkappaB (NF-kappaB, IkappaBalpha, and I-kappaBbeta), which is associated with inhibition of GM-CSF release[2].
In Vivo: It has previously been reported that treatment with Dexamethasone (Hexadecadrol) at a dose of 2x5 mg/kg efficiently inhibits lipopolysaccharide (LPS)-induced inflammation. In our experimental system, treatment with a single dose of Dexamethasone 10 mg/kg (i.p.) significantly decreases recruitment of granulocytes as well as spontaneous production of oxygen radicals compared with animals expose to LPS and injected with solvent alone (saline). The effects are statistically significant when administered both 1 h before and 1 h after inhalation of LPS. The number of granulocytes in BALF decreased to levels comparable to healthy animals (given an aerosol of water)[3].
Rats treated with Dexamethasone consume less food and weighed less than control rats. Treated rats also weigh less than pair-fed animals though their food intake is similar. Five days of Dexamethasone injection result in a significant increase in both the liver mass (+42%) and the liver to body weight ratio (+65%). The wet weight of gastrocnemius muscle decreases 20% after 5 days of treatment, but it remains unaffected relative to body weight (g/100 g body weight), indicating that muscle weight loss paralleled body weight loss[4].
Research Area
Cancer; Infection; Endocrinology; Inflammation/Immunology

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 500mg
Lieferbar: In stock
lieferbar

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?
 
Schließen